The Prognostic Value of the Advanced Lung Cancer Inflammation Index for Major Cardiovascular and Cerebrovascular Events in Patients with Non-ST Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention

<b>Objectives:</b> Our aim was to investigate whether admission advanced lung cancer inflammation index (ALI) values have a prognostic role on one-year major adverse cardiovascular and cerebrovascular events (MACCEs) in non-ST elevation myocardial infarction (NSTEMI) patients undergoing percutaneous coronary intervention (PCI). <b>Methods:</b> Our study consisted of 1173 consecutive patients aged 61.9 ± 12.5 years. The study population was divided into two groups according to the occurrence of MACCEs. BMI (body mass index), serum albumin levels and NLR (neutrophil to lymphocyte ratio) of patients were collected from hospital records, and ALI was calculated based on the following formula: BMI × serum albumin/NLR. We also calculated neutrophil to lymphocyte ratio (NLR), C-reactive protein/albumin ratio (CAR) and uric acid to albumin ratio (UAR) and investigated the association of these inflammation-based biomarkers with one-year MACCEs. <b>Results:</b> During the 12-month follow-up period, 158 (13.5%) patients had MACCEs, 55 (4.7%) of whom had all-cause mortality, 96 (8.2%) had nonfatal MI and 7 (0.6%) had nonfatal stroke. Patients with MACCEs had significantly lower ALI (<i>p</i> < 0.001), and also ALI (area under the curve [AUC] = 0.658, <i>p</i> < 0.001) had better discriminatory power and predictive accuracy in determining one-year MACCEs compared to albumin (AUC = 0.594, <i>p</i> < 0.001), NLR (AUC = 0.631, <i>p</i> < 0.001), CAR (AUC = 0.595, <i>p</i> < 0.001) and UAR (AUC = 0.577, <i>p</i> = 0.001) in the ROC analysis. Individuals with an ALI value lower than 43.9 were at greater risk of developing MACCEs (<i>p</i> < 0.001) due to the Delong test. <b>Conclusions:</b> Determining the level of ALI may have the potential to improve risk prognostication in NSTEMI patients undergoing revascularization therapy.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Medicine
Published
2025-02-20
DOI
https://doi.org/10.3390/jcm14051403
Citations
3
Primary Topic
Inflammatory Biomarkers in Disease Prognosis
Type
article
Field-Weighted Citation Impact
3.14
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The Prognostic Value of the Advanced Lung Cancer Inflammation Index for Major Cardiovascular and Cerebrovascular Events in Patients with Non-ST Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention

Ersan Oflar, Kıvanç Keskin, Muhsin Kalyoncuoğlu, Mehmet Baran Karataş et al.
3 citations
Journal of Clinical Medicine
Inflammatory Biomarkers in Disease Prognosis
3.14
article

The Prognostic Value of the Advanced Lung Cancer Inflammation Index for Major Cardiovascular and Cerebrovascular Events in Patients with Non-ST Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention

Ersan Oflar, Kıvanç Keskin, Muhsin Kalyoncuoğlu, Mehmet Baran Karataş, Ahmet Zengin, Semih Eren, Mehmet Karaca, Ali Nazmi Çalık
article en
3 citations

Abstract

<b>Objectives:</b> Our aim was to investigate whether admission advanced lung cancer inflammation index (ALI) values have a prognostic role on one-year major adverse cardiovascular and cerebrovascular events (MACCEs) in non-ST elevation myocardial infarction (NSTEMI) patients undergoing percutaneous coronary intervention (PCI). <b>Methods:</b> Our study consisted of 1173 consecutive patients aged 61.9 ± 12.5 years. The study population was divided into two groups according to the occurrence of MACCEs. BMI (body mass index), serum albumin levels and NLR (neutrophil to lymphocyte ratio) of patients were collected from hospital records, and ALI was calculated based on the following formula: BMI × serum albumin/NLR. We also calculated neutrophil to lymphocyte ratio (NLR), C-reactive protein/albumin ratio (CAR) and uric acid to albumin ratio (UAR) and investigated the association of these inflammation-based biomarkers with one-year MACCEs. <b>Results:</b> During the 12-month follow-up period, 158 (13.5%) patients had MACCEs, 55 (4.7%) of whom had all-cause mortality, 96 (8.2%) had nonfatal MI and 7 (0.6%) had nonfatal stroke. Patients with MACCEs had significantly lower ALI (<i>p</i> < 0.001), and also ALI (area under the curve [AUC] = 0.658, <i>p</i> < 0.001) had better discriminatory power and predictive accuracy in determining one-year MACCEs compared to albumin (AUC = 0.594, <i>p</i> < 0.001), NLR (AUC = 0.631, <i>p</i> < 0.001), CAR (AUC = 0.595, <i>p</i> < 0.001) and UAR (AUC = 0.577, <i>p</i> = 0.001) in the ROC analysis. Individuals with an ALI value lower than 43.9 were at greater risk of developing MACCEs (<i>p</i> < 0.001) due to the Delong test. <b>Conclusions:</b> Determining the level of ALI may have the potential to improve risk prognostication in NSTEMI patients undergoing revascularization therapy.

Journal of Clinical MedicineVol. 14(5)
Üsküdar University (TR), Bakırköy Dr.Sadi Konuk Eğitim ve Araştırma Hastanesi (TR), Sağlık Bilimleri Üniversitesi (TR), Dr. Siyami Ersek Göğüs Kalp Ve Damar Cerrahisi Eğitim Ve Araştırma Hastanesi (TR)
Reduced inequalities
Openalex Percentile: Top 9%
Inflammatory Biomarkers in Disease Prognosis
3.14
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.